Meeting
2017 ASCO Annual Meeting
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).
Authors
Mehra Golshan
Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA
Mehra Golshan , Sibylle Loibl , Jens Bodo Huober , Joyce O'Shaughnessy , Hope S. Rugo , Norman Wolmark , Mark D. McKee , David Maag , Danielle Marie Sullivan , Vincent L. Giranda , Xuan Liu , Gunter Von Minckwitz , Charles E. Geyer Jr., William M. Sikov , Michael Untch
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Local-Regional Therapy
Clinical Trial Registration Number
NCT02032277
Citation
J Clin Oncol 35, 2017 (suppl; abstr 514)
DOI
10.1200/JCO.2017.35.15_suppl.514
Abstract #
514
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.
First Author: Tiffany P. Avery
Poster
2017 ASCO Annual Meeting
Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).
First Author: Charles E. Geyer Jr.
Poster
2014 ASCO Annual Meeting
Phase III study evaluating safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy in subjects with early-stage triple-negative breast cancer (TNBC).
First Author: Gunter Von Minckwitz
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra